The BugTheDrug project sought to address the significant challenge of individual variability in drug response, a concern that impacts not only patients and caregivers, but also strains healthcare systems worldwide. Medications are developed to be processed by the human body – absorbed, metabolised, transported, and ultimately eliminated – to achieve their intended therapeutic effect. These pharmacokinetic properties, assessed during drug development, guide the determination of optimal dosages. Yet, individual differences in genetic makeup can lead to diverse drug responses, with some individuals metabolising drugs slower or less efficiently. Lifestyle factors, including diet and exercise, alongside the gut microbiome, which can extensively metabolise commonly prescribed drugs, further complicate drug response predictability. The composition of gut microbes, varying significantly among individuals due to diet and age, necessitates novel approaches for optimal drug response management.
In response, the BugTheDrug project developed an innovative computational framework that integrates genetic, dietary, and microbial data to predict an individual's drug response. This forward-thinking approach aimed to enable personalised treatment strategies, moving away from a currently pervasive one-size-fits-all mentality. The project achieved its goals through several key objectives:
The creation of novel computational methods to account for the highly complex interdependencies between human, microbial, dietary, and drug metabolism.
The creation of digital models of humans and associated microbes that allow for the personalised prediction of drug responses based on customisable queries and input data, such as genetic makeup, diet, and gut microbiome composition
The application and validation of these novel technologies in the context of colon cancer and Parkinson’s disease.
The project's conclusions underscore its transformative potential in precision health care. The development of digital metabolic twins represents a leap forward in creating personalised health interventions based on mechanism-derived hypotheses. By fostering a vast network of stakeholders from academia, industry, policy, regulators, and society, BugTheDrug has not only paved the way for technological advancements in healthcare, as demonstrated by the total expected 45 scientific manuscripts, but also ensured these innovations are accessible and beneficial to all, as demonstrated by the successful Virtuome programme with focus on community engagement. This initiative has laid a solid foundation for future exploration and expansion, evidenced by securing further funding ensuring the project's lasting impact and evolution.
